Welcome to our dedicated page for WATERS /DE/ SEC filings (Ticker: WAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on WATERS /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into WATERS /DE/'s regulatory disclosures and financial reporting.
WATERS CORP (WAT) filed an initial ownership report for Wu Tong, who serves as SVP Waters Analytical Sciences. This Form 3 establishes Wu Tong as a reporting officer for securities ownership disclosure purposes. The filing reports no transactions or specific holdings at this time and includes a Power of Attorney authorization.
WATERS CORP (symbol WAT) reports an executive leadership change in its Waters Analytical Sciences Division. On August 17, 2026, Robert L. Carpio III notified the company of his decision to resign from his role as Senior Vice President, Waters Analytical Sciences Division to pursue other opportunities, and he relinquished his duties effective August 20, 2026.
Tina Wu, currently Senior Vice President, Waters Materials Sciences Division and President, China, will assume the role of Senior Vice President, Waters Analytical Sciences Division. Ms. Wu joined Waters in June 2026 and has more than two decades of global business-to-business leadership experience across R&D, commercial operations and manufacturing, including over 20 years at DuPont where she led businesses with approximately $1 billion to $2.3 billion in annual net sales and most recently served as Global Vice President, President of DuPont Mobility & Materials since 2021.
Waters Corporation reported sharply higher scale in 2026 following completion of the $12.96 billion acquisition of BD’s Biosciences and Diagnostic Solutions business. For the quarter ended July 4, 2026, total net revenues were $1.65 billion, up from $771 million a year earlier, driven by adding Biosciences and Advanced Diagnostics alongside the legacy analytical instruments business.
Profitability deteriorated as integration-related costs and amortization flowed through. The quarter showed an operating loss of $86 million versus $188 million of operating income a year earlier, with purchased intangibles amortization of $244 million and restructuring charges of $49 million. Net loss was $136 million for the quarter and $208 million for the first half, compared with net income of $147 million and $268 million in the prior-year periods.
The balance sheet expanded significantly: total assets rose to $24.75 billion, including $9.42 billion of goodwill and $8.52 billion of intangible assets. Debt increased to $5.09 billion, mainly from new Senior Notes and a SpinCo term loan used in the transaction, while cash and cash equivalents stood at $539 million. Waters also implemented a workforce reduction affecting about 3% of employees, recording $52 million of severance-related restructuring costs.
Waters Corp director Christopher A. Kuebler reported exercising stock options for 3,626 shares of common stock on August 6, 2026, at 136.4300 per share.
On the same date he sold 3,626 common shares at 397.9400 per share in a transaction described as a sale in open market or private transaction.
Waters Corporation reported strong top-line growth for the quarter ended July 4, 2026, with net revenue of $1.645 billion, up from $771 million a year earlier. Organic revenue was $828 million versus $771 million, representing 7% organic reported growth and 9% in constant currency, while the recently acquired Biosciences and Diagnostic Solutions businesses contributed $817 million. By division, Analytical Sciences delivered $669 million, Biosciences $368 million, Advanced Diagnostics $521 million, and Materials Sciences $87 million.
Despite this growth, acquisition-related purchase accounting charges and other costs led to a GAAP diluted loss per share of $(1.39), compared with EPS of $2.47 in the prior-year quarter. Adjusted diluted EPS rose to $3.05 from $2.95. Operating cash flow for the quarter was $200 million and adjusted free cash flow was $202 million. The company raised full-year 2026 guidance, now expecting total revenue of $6.415–$6.476 billion and adjusted EPS of $14.45–$14.65, implying 7–9% organic constant currency revenue growth. Debt increased to $5.086 billion at July 4, 2026, reflecting financing for recent acquisitions, while total stockholders’ equity rose to $15.195 billion.
Waters Corp director Heather Knight reported a compensation-related equity award rather than a market trade. She acquired 63.03 common stock units of Waters common stock at a stated price of $0.00 per unit, bringing her direct holdings to 1,280.54 common stock units.
According to the disclosure, these common stock units were received in lieu of cash payment of director fees under the company’s 1996 Non-Employee Director Deferred Compensation Plan. The units are convertible into an equal number of Waters common shares upon distribution, which is scheduled to occur on January 1, 2027, based on a prior election.
Waters Corp director Wei Jiang reported a grant of common stock units received as board compensation. On this Form 4, Jiang acquired 67.42 common stock units at a stated price of $0.00 per unit, increasing direct holdings to 3,572.75 common stock units.
According to the filing, these units were received in lieu of cash payment of director fees under Waters Corp's 1996 Non-Employee Director Deferred Compensation Plan. Each common stock unit is convertible into one share of Waters Corp common stock upon distribution, which will occur automatically when Jiang's service on the board terminates.
Waters Corp SVP Robert L. Carpio III reported a routine tax-related share disposition. On June 24, 2026, 189 shares of Waters common stock were withheld by the company to cover tax obligations tied to the vesting of previously reported restricted stock units.
These shares were not sold on the open market but used to satisfy withholding requirements. After this transaction, Carpio directly holds 3,426 shares of Waters common stock.
Waters Corporation reported the results of its annual stockholder meeting, where approximately 90,729,508 shares, or about 92.4% of shares entitled to vote, were present or represented by proxy. Stockholders re-elected all nominated directors to the Board, with each candidate receiving a substantial majority of votes cast.
Stockholders also approved the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, they adopted a non-binding, advisory resolution approving the compensation paid to the company’s named executive officers.